Implementation and Perspectives of CROs (2025)

Douglas Henry & Steven Tan

Expanding the Pharmaverse beyond Clinical Reporting

2025
CRO
Authors

Douglas Henry

Steven Tan

Published

September 15, 2025

Perspectives of CROs

Chairs: Douglas Henry and Steven Tan

Current Industry Landscape

  • SAS Dominance: SAS remains a major part of CRO workflows and processes
  • Innovation Gap: Differentiation between innovative CROs (smaller, forward-thinking) and traditional CROs (larger, dominant market players)

Key Challenges for CROs

  • Upskilling Requirements: Need to invest in training staff on new technologies while maintaining SAS capabilities
  • Dual Technology Management: Challenge of managing both traditional and modern toolchains
  • Guidance Dependency: Many CROs seeking more direction from sponsor companies rather than self-directing change
  • Business Model Constraints: Traditional “order taker” model doesn’t align well with consulting-style technology guidance

CRO as Resource vs. Bottleneck

  • Bottleneck Risk: CROs can become bottlenecks when trying to figure out technology transitions independently
  • Valuable Resource Potential: CROs have extensive cross-client experience that could be leveraged for best practices
  • Service Evolution: Pivoting from process-focused to more consultative roles as clients demand technology expertise

Community Engagement

  • Information Access: Importance of CROs participating in organizations like R/Pharma for knowledge sharing
  • Ecosystem Integration: CROs are significant players in the overall life sciences technology ecosystem
  • Increased Participation: Need for more CRO involvement in industry technology discussions